Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: lian q. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Turner N, et al. Among authors: lian q. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3. Breast Cancer Res Treat. 2022. PMID: 34860318 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S. Guthrie H, et al. Among authors: lian q. J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134. J Alzheimers Dis. 2020. PMID: 32568196 Free PMC article. Clinical Trial.
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
Rios-Romenets S, Lopera F, Sink KM, Hu N, Lian Q, Guthrie H, Smith J, Cho W, Mackey H, Langbaum JB, Thomas RG, Giraldo-Chica M, Tobon C, Acosta-Baena N, Muñoz C, Ospina P, Tirado V, Henao E, Bocanegra Y, Chen K, Su Y, Goradia D, Thiyyagura P, VanGilder PS, Luo J, Ghisays V, Lee W, Malek-Ahmadi MH, Protas HD, Chen Y, Quiroz YT, Reiman EM, Tariot PN; the API ADAD Colombia Trial Group. Rios-Romenets S, et al. Among authors: lian q. Alzheimers Dement. 2020 Jul;16(7):1023-1030. doi: 10.1002/alz.12109. Epub 2020 May 17. Alzheimers Dement. 2020. PMID: 32418361 Free PMC article.
Epidemic Features and Megagenomic Analysis of Childhood Mycoplasma Pneumoniae post COVID-19 Pandemic: A 6-year Study in Southern China.
Xu Y, Yang C, Sun P, Zeng F, Wang Q, Wu J, Fang C, Zhang C, Wang J, Gu Y, Wu X, Zhang X, Yang B, Yang J, Zhang H, Lian J, Zhang J, Huang L, Lian Q. Xu Y, et al. Among authors: lian q. Emerg Microbes Infect. 2024 May 9:2353298. doi: 10.1080/22221751.2024.2353298. Online ahead of print. Emerg Microbes Infect. 2024. PMID: 38721691
713 results